Skip to main navigation
Skip to search
Skip to main content
UTMB Health Research Expert Profiles Home
Help & FAQ
Home
Experts
Departments
Equipment
Projects/Grants
Publications
Activities
Press/Media
Honors
Impacts
Search by expertise, name or affiliation
The future of cancer treatment: combining radiotherapy with immunotherapy
Gunjan Dagar
, Ashna Gupta
, Abhishek Shankar
, Ravi Chauhan
, Muzafar A. Macha
, Ajaz A. Bhat
, Dayasagar Das
, Rajeev Goyal
, Sandeep Bhoriwal
, Raj K. Pandita
, Chandra Prakash Prasad
,
Partha S. Sarkar
, Tej K. Pandita
, Mayank Singh
Neurobiology
Research output
:
Contribution to journal
›
Review article
›
peer-review
17
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'The future of cancer treatment: combining radiotherapy with immunotherapy'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Cancer Treatment
100%
Radiotherapy
100%
DNA Damage
50%
Cancer Cells
50%
DNA Repair
33%
DNA Damage Response
33%
Adverse Effects
16%
Therapeutic Strategies
16%
Immune Response
16%
Signaling Pathway
16%
Paucity
16%
Anti-cytotoxic
16%
Tumor Cells
16%
Repair Method
16%
Clinical Practice
16%
Clinical Outcomes
16%
Beneficial Effects
16%
Programmed Cell Death
16%
In Cancer
16%
Synergistic Mechanism
16%
Novel Treatments
16%
DNA Damage Response Pathway
16%
Anti-tumor Response
16%
Programmed Death-ligand 1 (PD-L1)
16%
Increased Incidence
16%
Small Molecule Drugs
16%
Optimal Dose
16%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
16%
Genetic Material
16%
Randomized Trial
16%
Clinical Toxicity
16%
Molecular Strategies
16%
Toxicity Profile
16%
Survival Benefit
16%
Dosing Schedule
16%
Practice Profile
16%
Concurrent Use
16%
Open Area
16%
DNA Repair Deficiency
16%
Damage Mechanism
16%
Trial Data
16%
High-dose Radiation
16%
Metastatic Malignancy
16%
Tumor Cell Death
16%
Immunotherapy Agents
16%
Radioimmunotherapy
16%
Practice Outcomes
16%
Pathways in Cancer
16%
Outcome Profiles
16%
Sequential Use
16%
Anti-programmed Cell Death Protein 1
16%
Concurrent Probability
16%
Medicine and Dentistry
Cancer Treatment
100%
Immunotherapy
100%
Radiation Therapy
100%
Cancer Cell
50%
DNA Repair
50%
DNA Damage
50%
DNA Damage Response
50%
Tumor Cell
33%
Cancer Therapy
16%
Neoplasm
16%
Immune Response
16%
Cancer
16%
Cell Signaling Pathway
16%
Drug Megadose
16%
Cell Death
16%
CTLA-4
16%
Optimal Drug Dose
16%
Programmed Death 1 Receptor
16%
Radioimmunotherapy
16%
Adverse Effect
16%
Programmed Cell Death
16%
Immunology and Microbiology
Immunotherapy
100%
DNA Repair
50%
Cancer Cell
50%
DNA Damage
50%
DNA Damage Response
50%
Tumor Cell
33%
Cell Death
33%
Immune Response
16%
Drug Megadose
16%
CTLA-4
16%
Optimal Drug Dose
16%
Programmed Death 1 Receptor
16%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Immunotherapy
100%
Neoplasm
50%
Programmed Cell Death
16%
Programmed Death 1 Receptor
16%
Cytotoxic T Lymphocyte Antigen 4
16%